{"id":22804,"date":"2026-03-07T16:05:45","date_gmt":"2026-03-07T16:05:45","guid":{"rendered":"https:\/\/readtrends.com\/en\/pilates-lymphoma-car-t\/"},"modified":"2026-03-07T16:05:45","modified_gmt":"2026-03-07T16:05:45","slug":"pilates-lymphoma-car-t","status":"publish","type":"post","link":"https:\/\/readtrends.com\/en\/pilates-lymphoma-car-t\/","title":{"rendered":"Pilates Instructor Mistook Flu for Aggressive Lymphoma; CAR-T Brought Remission"},"content":{"rendered":"<article>\n<p>In January 2024 a New Jersey Pilates teacher, Debi Weiss, dismissed growing breathlessness and fatigue as the flu until symptoms escalated and she sought medical care in March. Tests revealed diffuse large B-cell lymphoma, an aggressive blood cancer that had returned and spread to her brain after initial chemotherapy. Her care team at Atlantic Health Morristown Medical Center recommended personalized CAR\u2011T cell therapy, which Weiss received in January 2025. As of March 2026 she is in complete remission and continues routine scans to monitor for recurrence.<\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li>Patient timeline: symptoms began January 2024, initial diagnosis in March 2024, CAR\u2011T infusion in January 2025, monitored for one year and now in complete remission (March 2026).<\/li>\n<li>Diagnosis: diffuse large B\u2011cell lymphoma, a common and fast\u2011growing subgroup of lymphomas with roughly 25,000 U.S. cases per year.<\/li>\n<li>Treatment choice: CAR\u2011T immunotherapy was selected after lymphoma recurred in the brain one month post\u2011chemotherapy; CAR\u2011T cells are engineered T\u2011cells infused back into the patient.<\/li>\n<li>Procedure details: the engineered cell infusion typically takes 20\u201330 minutes and patients are commonly observed in hospital for one to two weeks because of potential neurotoxicity.<\/li>\n<li>Outcome: Weiss experienced no reported acute side effects from CAR\u2011T, regained daily function, and is currently without evidence of disease while undergoing periodic scans every four to six months.<\/li>\n<li>Prognosis note: clinicians said if remission holds for three years the chance of recurrence is substantially lower.<\/li>\n<\/ul>\n<h2>Background<\/h2>\n<p>Diffuse large B\u2011cell lymphoma (DLBCL) is the most frequent type of non\u2011Hodgkin lymphoma, representing a fast\u2011growing malignancy of B lymphocytes. In the United States clinicians diagnose roughly 25,000 new cases of DLBCL annually; it can present with systemic symptoms such as fatigue and shortness of breath that may be mistaken for common illnesses like influenza. First\u2011line treatment commonly includes combination chemotherapy, which attacks rapidly dividing cells but can fail if cancer recurs quickly afterward. When relapse occurs soon after standard chemotherapy, oncologists often consider biologic options that harness the immune system rather than additional cytotoxic regimens.<\/p>\n<p>CAR\u2011T (chimeric antigen receptor T\u2011cell) therapy has emerged over the past decade as one such biologic option, approved for several blood cancers including relapsed or refractory DLBCL. The approach removes a patient\u2019s T cells, engineers them to target tumor antigens, expands them in the lab, and reinfuses them into the bloodstream. Given the therapy\u2019s power and risks \u2014 notably cytokine release syndrome and neurologic toxicity \u2014 patients typically undergo inpatient monitoring for days to weeks post\u2011infusion. Use is concentrated at specialized centers and is expanding in clinical trials for other hematologic and autoimmune conditions.<\/p>\n<h2>Main Event<\/h2>\n<p>Debi Weiss first noticed progressive weakness and trouble breathing in January 2024 but delayed care until March when symptoms became debilitating and she could no longer walk her dog. Primary care evaluation triggered blood work and imaging; a biopsy confirmed diffuse large B\u2011cell lymphoma. Weiss began standard chemotherapy and initially tolerated treatment with fatigue as the main side effect, according to her treatment team.<\/p>\n<p>One month after completing chemotherapy, Weiss developed neurologic symptoms that prompted repeat imaging; clinicians found the lymphoma had recurred and involved the brain. Her hematologist\u2011oncologist, Dr. Charles Farber at Atlantic Health Morristown Medical Center, described her outlook as poor without a different approach. The multidisciplinary team evaluated Weiss for personalized CAR\u2011T therapy, explaining potential benefits and risks and obtaining approval and preparation for the procedure.<\/p>\n<p>In January 2025 Weiss received the engineered T\u2011cell infusion. The transfer of cells into her bloodstream took roughly 20\u201330 minutes; nursing staff monitored cognitive and neurologic status closely afterward. Weiss later described a vivid impression of her reinfused cells attacking the tumor, an image staff lightened with whiteboard drawings during her stay. Over the following days and weeks she showed no acute complications such as neurotoxicity or cytokine release syndrome and was discharged to continue outpatient follow\u2011up.<\/p>\n<p>Following the infusion Weiss returned to normal activities: walking her dog, resuming part\u2011time work and participating in survivor support activities. Atlantic Health clinicians report she remained under surveillance with scans every four to six months. As of the latest clinical update she has no evidence of disease; the team will continue periodic imaging and follow\u2011up care to detect any recurrence early.<\/p>\n<h2>Analysis &#038; Implications<\/h2>\n<p>Weiss\u2019s case illustrates how DLBCL can masquerade as benign viral illness initially and underscores the importance of clinical vigilance when systemic symptoms persist. Early recognition and biopsy are crucial because DLBCL often progresses rapidly; delayed diagnosis can narrow therapeutic options. Clinicians balance the toxicity of repeat chemotherapy with the potential durability of immune\u2011based therapies when disease recurs shortly after standard treatment.<\/p>\n<p>CAR\u2011T therapy represents a paradigm shift for relapsed hematologic malignancies: by genetically programming a patient\u2019s immune cells to target cancer, it can produce deep, durable remissions that traditional cytotoxic chemotherapy may not achieve. However, CAR\u2011T is resource\u2011intensive, requiring specialized manufacturing, inpatient monitoring, and expertise to manage immune\u2011mediated toxicities. Access remains uneven geographically and economically, which affects who can receive these therapies.<\/p>\n<p>From a systems perspective, expanding CAR\u2011T indications and manufacturing capacity will affect oncology practice patterns and healthcare spending. Payers and providers face decisions about which patients are best served by CAR\u2011T versus other approaches, and long\u2011term outcome data will shape value assessments. Ongoing trials investigating CAR\u2011T for autoimmune diseases or solid tumors could broaden the technology\u2019s footprint but also raise new safety and cost questions.<\/p>\n<h2>Comparison &#038; Data<\/h2>\n<figure>\n<table>\n<thead>\n<tr>\n<th>Item<\/th>\n<th>Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Annual U.S. DLBCL cases<\/td>\n<td>~25,000<\/td>\n<\/tr>\n<tr>\n<td>Symptom onset<\/td>\n<td>January 2024<\/td>\n<\/tr>\n<tr>\n<td>Initial diagnosis<\/td>\n<td>March 2024<\/td>\n<\/tr>\n<tr>\n<td>CAR\u2011T infusion<\/td>\n<td>January 2025<\/td>\n<\/tr>\n<tr>\n<td>Typical infusion time<\/td>\n<td>20\u201330 minutes<\/td>\n<\/tr>\n<tr>\n<td>Post\u2011infusion observation<\/td>\n<td>1\u20132 weeks (common)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p>The table summarizes case\u2011specific dates and typical procedural benchmarks for CAR\u2011T therapy. While Weiss\u2019s infusion required only the short procedure time typical of CAR\u2011T, the broader care pathway includes lymphocyte collection, genetic modification, cell expansion and inpatient monitoring, extending the total treatment timeline to several weeks. Comparative outcomes across centers vary; remission durability depends on disease biology, prior therapies and patient factors. Longitudinal registries and clinical trials continue to refine expected success rates and complication profiles.<\/p>\n<h2>Reactions &#038; Quotes<\/h2>\n<blockquote>\n<p>&#8220;It was a bit of a shock \u2014 it was very much an out\u2011of\u2011body experience.&#8221;<\/p>\n<p><cite>Debi Weiss<\/cite><\/p><\/blockquote>\n<p>Weiss used the phrase to describe the emotional upheaval of an unexpected cancer diagnosis and the disorienting transition from healthy activity to intensive oncology care. That sense of disbelief is a common patient response and highlights the psychological as well as physical burden of a fast\u2011moving malignancy.<\/p>\n<blockquote>\n<p>&#8220;When cancer recurs shortly after chemotherapy, giving more poisons isn&#8217;t usually the answer.&#8221;<\/p>\n<p><cite>Dr. Charles Farber, Hematologist\u2011Oncologist, Atlantic Health Morristown Medical Center<\/cite><\/p><\/blockquote>\n<p>Dr. Farber framed the clinical rationale for considering CAR\u2011T: repeat cytotoxic regimens may offer limited benefit after early relapse, whereas targeted cellular therapies can harness the immune system to seek residual disease. He emphasized multidisciplinary evaluation before initiating complex therapies.<\/p>\n<blockquote>\n<p>&#8220;The potential applications are endless.&#8221;<\/p>\n<p><cite>Dr. Mohamad Cherry, Medical Director of Hematology, Atlantic Health<\/cite><\/p><\/blockquote>\n<p>Dr. Cherry\u2019s comment reflects enthusiasm for expanding CAR\u2011T research but should be read in context: ongoing studies are required to establish safety, efficacy and cost\u2011effectiveness across new indications. Clinicians caution that translation from hematologic malignancies to other diseases is not guaranteed.<\/p>\n<aside>\n<details>\n<summary>Explainer: What is CAR\u2011T therapy?<\/summary>\n<p>CAR\u2011T stands for chimeric antigen receptor T\u2011cell therapy. It modifies a patient\u2019s own T cells to recognize a specific antigen on cancer cells, then reinfuses the cells to attack the tumor. The process includes leukapheresis to collect T cells, laboratory engineering and expansion, lymphodepleting chemotherapy in the patient, and the final cell infusion. Risks include cytokine release syndrome and neurologic toxicity; management protocols and center experience are important for safety. CAR\u2011T has been approved for several blood cancers and is under study for other diseases.<\/p>\n<\/details>\n<\/aside>\n<h3>Unconfirmed<\/h3>\n<ul>\n<li>Claims that CAR\u2011T will be a safe, routinely available cure for all relapsed DLBCL patients are not established and depend on individual disease and center factors.<\/li>\n<li>Early reports of CAR\u2011T applications in autoimmune diseases are experimental; broader clinical benefit and safety remain under investigation.<\/li>\n<\/ul>\n<h2>Bottom Line<\/h2>\n<p>Weiss\u2019s experience highlights both the promise and complexity of modern cancer care: rapid progression of diffuse large B\u2011cell lymphoma can disguise itself as a common illness, but advanced immunotherapies such as CAR\u2011T can deliver durable remissions for select patients. Her favorable outcome\u2014no evidence of disease as of March 2026\u2014reflects timely diagnosis, access to specialized care and careful post\u2011treatment monitoring.<\/p>\n<p>For clinicians and health systems, cases like this reinforce the need for early diagnostic evaluation of persistent systemic symptoms and equitable access to specialized therapies. For patients, Weiss\u2019s story underscores the value of shared decision\u2011making with a multidisciplinary team and the importance of ongoing surveillance after remission.<\/p>\n<h3>Sources<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.cbsnews.com\/news\/lymphoma-cancer-immunotherapy-atlantic-health-morristown-new-jersey\/\" target=\"_blank\" rel=\"noopener\">CBS News (news report)<\/a><\/li>\n<li><a href=\"https:\/\/www.atlantichealth.org\/\" target=\"_blank\" rel=\"noopener\">Atlantic Health Morristown Medical Center (hospital\/clinical source)<\/a><\/li>\n<li><a href=\"https:\/\/www.mskcc.org\/\" target=\"_blank\" rel=\"noopener\">Memorial Sloan Kettering Cancer Center \u2014 DLBCL information (academic\/clinical resource)<\/a><\/li>\n<li><a href=\"https:\/\/www.lls.org\/\" target=\"_blank\" rel=\"noopener\">Leukemia &#038; Lymphoma Society (patient advocacy\/clinical information)<\/a><\/li>\n<\/ul>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>In January 2024 a New Jersey Pilates teacher, Debi Weiss, dismissed growing breathlessness and fatigue as the flu until symptoms escalated and she sought medical care in March. Tests revealed diffuse large B-cell lymphoma, an aggressive blood cancer that had returned and spread to her brain after initial chemotherapy. Her care team at Atlantic Health &#8230; <a title=\"Pilates Instructor Mistook Flu for Aggressive Lymphoma; CAR-T Brought Remission\" class=\"read-more\" href=\"https:\/\/readtrends.com\/en\/pilates-lymphoma-car-t\/\" aria-label=\"Read more about Pilates Instructor Mistook Flu for Aggressive Lymphoma; CAR-T Brought Remission\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":22799,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_title":"Pilates instructor's lymphoma reversed by CAR\u2011T | DeepHealth","rank_math_description":"A New Jersey Pilates instructor first thought she had the flu in January 2024; after a March diagnosis of diffuse large B\u2011cell lymphoma and CAR\u2011T therapy in January 2025, she is now in complete remission.","rank_math_focus_keyword":"lymphoma,CAR-T,immunotherapy,diffuse large B-cell lymphoma,Debi Weiss","footnotes":""},"categories":[2],"tags":[],"class_list":["post-22804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-top-stories"],"_links":{"self":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/22804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/comments?post=22804"}],"version-history":[{"count":0,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/posts\/22804\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media\/22799"}],"wp:attachment":[{"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/media?parent=22804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/categories?post=22804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readtrends.com\/en\/wp-json\/wp\/v2\/tags?post=22804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}